This is a US news story, published by Wired, that relates primarily to Zepbound news.
For more US news, you can click here:
more US newsFor more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Wired, you can click here:
more news from WiredOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
tirzepatide medications. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest tirzepatide patient news, tirzepatide patients news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
loss drug ZepboundWired
•
72% Informative
The US Food and Drug Administration announced tirzepatide is no longer in shortage.
The active ingredient in the weight-loss drug Zepbound and diabetes medication Mounjaro has experienced runaway popularity.
In the US , when drugs are in shortage, pharmacies can produce custom copies of them.
Some telehealth providers, like Henry Meds , are still advertising and selling compounded tirzepatide.
Eli Lilly says it is exploring all options to address the patient safety risks posed by counterfeit, fake, and illegal.
A drug compounding industry group called the Outsourcing Facilities Association filed a lawsuit against the FDA on October 7 .
The cost of drugs does not factor into whether they are in official shortage or not.
The affordability of these medications is directly connected to how accessible many patients find them.
The removal of compounded options from the market could lead to a rush toward counterfeit GLP-1s or research peptides.
VR Score
54
Informative language
41
Neutral language
71
Article tone
informal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
13
Source diversity
12
Affiliate links
no affiliate links